Next Plant-Based Unicorn
The plant-based industry has been ignited. Pay close attention to this stock.
Learn more.
Regina M. Paglia, insider at Dicerna Pharmaceuticals

Regina M. Paglia Insider Information

Presently, Regina M. DeTore Paglia is Senior Vice President-Human Resources of Dicerna Pharmaceuticals, Inc.

She previously occupied the position of Vice President-Human Resources of Mascoma Corp., Senior Vice President-Human Resources at PTTGC Innovation America Corp., Manager-Human Resources at FMR LLC, Senior Vice President-Human Resources of Paratek Pharmaceuticals, Inc., Vice President-Human Resources for Sunovion Pharmaceuticals, Inc. and Director-Human Resources for Tufts Associated Health Plans, Inc.

She received a graduate degree from Framingham State College and an undergraduate degree from Sawyer Business School.

What is Regina M. Paglia's net worth?

The estimated net worth of Regina M. Paglia is at least $46,826.10 as of June 25th, 2021. Ms. Paglia owns 1,269 shares of Dicerna Pharmaceuticals stock worth more than $46,826 as of August 3rd. This net worth approximation does not reflect any other investments that Ms. Paglia may own.

How old is Regina M. Paglia?

Ms. Paglia is currently 62 years old. There are 8 older executives and no younger executives at Dicerna Pharmaceuticals. The oldest executive at Dicerna Pharmaceuticals is Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board, who is 74 years old.

How do I contact Regina M. Paglia?

The corporate mailing address for Ms. Paglia and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at 617-621-8097 and via email at [email protected]

Has Regina M. Paglia been buying or selling shares of Dicerna Pharmaceuticals?

Regina M. Paglia has not been actively trading shares of Dicerna Pharmaceuticals during the past quarter. Most recently, Regina M. Paglia sold 1,000 shares of the business's stock in a transaction on Friday, June 25th. The shares were sold at an average price of $38.00, for a transaction totalling $38,000.00. Following the completion of the sale, the insider now directly owns 1,269 shares of the company's stock, valued at $48,222.

Are insiders buying or selling shares of Dicerna Pharmaceuticals?

In the last year, Dicerna Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth mmore than $180,600.00. In the last year, insiders at the biopharmaceutical company sold shares 33 times. They sold a total of 1,328,889 shares worth mmore than $33,378,558.67. The most recent insider tranaction occured on July, 06th when James B Weissman COO bought 30,000 shares worth more than $1,172,700.00. Insiders at Dicerna Pharmaceuticals own 10.2 % of the company.

Information on this page was last updated on 7/6/2021.

Regina M. Paglia Insider Trading History at Dicerna Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/25/2021Sell1,000$38.00$38,000.001,269View SEC Filing Icon  
6/22/2021Sell18,435$36.99$681,910.6514,019View SEC Filing Icon  
6/16/2021Sell31,564$35.63$1,124,625.32381View SEC Filing Icon  
6/1/2021Sell4,431$30.94$137,095.144,431View SEC Filing Icon  
5/3/2021Sell4,431$30.28$134,170.684,431View SEC Filing Icon  
4/1/2021Sell4,431$25.86$114,585.664,431View SEC Filing Icon  
1/25/2021Sell6,326$25.00$158,150.006,326View SEC Filing Icon  
11/4/2020Sell30,000$22.75$682,500.0030,000View SEC Filing Icon  
See Full Table

Regina M. Paglia Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows Regina M Paglia's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $36.90
Low: $35.89
High: $37.29

50 Day Range

MA: $36.01
Low: $30.12
High: $39.99

2 Week Range

Now: $36.90
Low: $16.50
High: $40.14


499,470 shs

Average Volume

762,803 shs

Market Capitalization

$2.84 billion

P/E Ratio


Dividend Yield



Next Plant-Based Unicorn
The plant-based industry has been ignited. Pay close attention to this stock.
Learn more.